More recently, pharmacologic inhibition of the kinase mTOR has been shown to reduce angiomyolipoma volume in patients with TSC and sporadic LAM [8-10] and mTOR inhibitors are now recommended for treatment of angiomyolipoma in TSC [11]. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.